HepatoChem, a startup based on technology licensed from Princeton, wins funding from Massachusetts Life Sciences Center Accelerator Program
An early-stage life science company, HepatoChem is developing a platform for fast and cost effective assessment of metabolites and toxicity in drug development. Read More in this article from MarketWatch.com